TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15383481

Group type: EXPERIMENTAL
Intervention: Long-term oral anticoagulant (OAC) therapy (target INR 2.5; range 2.0 to 3.0) for patients with rheumatic mitral valve disease and AF or history of systemic embolism.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adding aspirin, 75 to 100 mg/d for patients with rheumatic mitral valve disease with AF or history of systemic embolism who suffer systemic embolism while receiving OACs at a therapeutic INR.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adding dipyridamole, 400 mg/d, or clopidogrel for patients unable to take aspirin.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term aspirin therapy, 50 to 162 mg/d for patients with MVP and documented but unexplained TIAs.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists for all patients with mechanical prosthetic heart valves.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target INR of 2.5 (range 2.0 to 3.0) for patients with St. Jude Medical bileaflet valve in the aortic position.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target INR of 3.0 (range 2.5 to 3.5) for patients with tilting disk valves and bileaflet mechanical valves in the mitral position.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target INR of 3.0 (range 2.5 to 3.5) in combination with aspirin, 75 to 100 mg/d for patients with caged ball or caged disk valves.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists with a target INR of 2.5 (range 2.0 to 3.0) for the first 3 months after valve insertion in the mitral position for patients with bioprosthetic valves.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term (> 3 months) therapy with aspirin, 75 to 100 mg/d for patients with bioprosthetic valves who are in sinus rhythm and do not have AF.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No antithrombotic therapy for patients with MVP without history of systemic embolism, unexplained TIAs, or AF.
Number of subjects: 0
Study: 10522839

Group type: EXPERIMENTAL
Intervention: Metformin plus repaglinide (MET/REP)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Metformin plus placebo (MET)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Repaglinide plus placebo (REP)
Number of subjects: 83
Study: 7760966

Group type: EXPERIMENTAL
Intervention: Simvastatin monotherapy (20 to 80 mg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Simvastatin in combination with other lipid-lowering agents
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Simvastatin (both monotherapy and combination therapy)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 44
Study: 2184703

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nefopam
Number of subjects: 60
Study: 452619

Group type: EXPERIMENTAL
Intervention: Nicomorphine diluted with water
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nicomorphine diluted with propylenglykol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Propylenglykol alone
Number of subjects: 120
Study: 31551222

Group type: EXPERIMENTAL
Intervention: High-dose ambroxol
Number of subjects: 180

Group type: COMPARATOR
Intervention: Small-dose ambroxol (Control)
Number of subjects: 180
Study: 28620884

Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixabepilone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirect response model with linear drug effect
Number of subjects: 0
Study: 25666311

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 24969152

Group type: EXPERIMENTAL
Intervention: Augmented Standard Care (ASC; lower dose)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Resource Nurse Care (RNC; medium dose)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Transitional Care Model (TCM; higher dose)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Functional Status
Number of subjects: 202
Study: 22713245

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GCs)
Number of subjects: 300000000
Study: 18066659

Group type: EXPERIMENTAL
Intervention: Self-guided reading plus nicotine patch (n = 18)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus nicotine patch (n = 22)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nicotine patch compliance
Number of subjects: 40
Study: 17870206

Group type: EXPERIMENTAL
Intervention: Brief Negotiated Interview (intervention group)
Number of subjects: 1132

Group type: COMPARATOR
Intervention: Control group (written handout)
Number of subjects: 1132
Study: 15168925

Group type: EXPERIMENTAL
Intervention: 0.06 mg x Kg(‐1) of rocuronium
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physiological saline solution
Number of subjects: 60
Study: 12217089

Group type: EXPERIMENTAL
Intervention: Internet training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 100
Study: 9613753

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (25-50 U per site, mean total dose 210 U, range 150-300 U)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Number of subjects: 5
Study: 7851518

Group type: EXPERIMENTAL
Intervention: Split-belt locomotion with varying belt speeds (0.5, 1.0, 1.5, 2.0 m/s)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Split-belt locomotion with faster ipsilateral belt speed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Split-belt locomotion with slower contralateral belt speed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Support phase on the faster side
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Support phase on the slower side
Number of subjects: 0
Study: 2680315

Group type: EXPERIMENTAL
Intervention: Single-dose therapy with sulfamethizole
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional six-day therapy with sulfamethizole
Number of subjects: 41
Study: 31669050

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (D group) - loading dose of 0.5 μg/kg for 10 min, maintained at 0.5 μg/kg/h until liver resection
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (C group) - 0.9% sodium chloride administered in the same volume and infusion rate as D group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (D group)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (C group)
Number of subjects: 58
Study: 30883366

Group type: EXPERIMENTAL
Intervention: Oro-and naso-pharyngeal suction (ONPS)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No oro-and naso-pharyngeal suction (No-ONPS)
Number of subjects: 84
Study: 28857498

Group type: EXPERIMENTAL
Intervention: Higher self‐regulatory efficacy (SRE‐flare) individuals
Number of subjects: 0
Study: 25894719

Group type: EXPERIMENTAL
Intervention: On-body injector
Number of subjects: 253

Group type: COMPARATOR
Intervention: Manual injection
Number of subjects: 253
Study: 23857075

Group type: EXPERIMENTAL
Intervention: Music (recordings selected by a music therapist via ambient speakers)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 42
Study: 21067717

Group type: EXPERIMENTAL
Intervention: rFSH + rLH administration
Number of subjects: 720

Group type: COMPARATOR
Intervention: rFSH administration
Number of subjects: 720
Study: 19085014

Group type: EXPERIMENTAL
Intervention: EPO treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 10
Study: 18181381

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (RI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Remifentanil infusion with paracervical block (RI + PCB)
Number of subjects: 40
Study: 14985684

Group type: EXPERIMENTAL
Intervention: Lactulose (5 g b.i.d. for 6 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (sucrose, 5 g b.i.d. for 6 weeks)
Number of subjects: 16
Study: 11449021

Group type: EXPERIMENTAL
Intervention: Home based muscle strengthening and balance retraining programme
Number of subjects: 233

Group type: COMPARATOR
Intervention: Usual care and social visits (control group)
Number of subjects: 233
Study: 9926154

Group type: EXPERIMENTAL
Intervention: Breathing Problems Questionnaire (BPQ)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Chronic Respiratory Disease Questionnaire (CRQ)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nottingham Extended ADL (NEADL)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Brief Assessment of Depression Cards (BASDEC)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 6‐min walk distance
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Resting oxygen saturation
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Household composition
Number of subjects: 96
Study: 8089468

Group type: EXPERIMENTAL
Intervention: Multiple drug regimen including a macrolide for treatment of DMAC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylaxis for patients with CD4 < 100 mm3
Number of subjects: 0
Study: 3185621

Group type: EXPERIMENTAL
Intervention: Outpatient cardiac catheterization
Number of subjects: 381

Group type: COMPARATOR
Intervention: Inpatient cardiac catheterization
Number of subjects: 381
Study: 30673688

Group type: EXPERIMENTAL
Intervention: Sitting
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Lying
Number of subjects: 46
Study: 28481431

Group type: EXPERIMENTAL
Intervention: Cognitive dissonance-based (DB) intervention
Number of subjects: 112

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 112
Study: 26025259

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy for the Dutch multidisciplinary guideline for nonspecific low back pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimedia intervention aimed at improving beliefs, cognitions, and self-management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive guideline dissemination
Number of subjects: 0
Study: 24111816

Group type: EXPERIMENTAL
Intervention: Diluted bleach baths (soaked for 10 min, twice a week for 2 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distilled water baths (placebo control)
Number of subjects: 0
Study: 21726992

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 16

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 16
Study: 17698067

Group type: EXPERIMENTAL
Intervention: Colonoscopy after screening colonoscopy in patients with neoplasia
Number of subjects: 3121

Group type: COMPARATOR
Intervention: Colonoscopy after screening colonoscopy in neoplasia-free controls
Number of subjects: 3121

Group type: EXPERIMENTAL
Intervention: Patients with 1 or 2 tubular adenomas <10 mm
Number of subjects: 3121

Group type: EXPERIMENTAL
Intervention: Patients with 3 or more tubular adenomas <10 mm
Number of subjects: 3121

Group type: EXPERIMENTAL
Intervention: Patients with tubular adenoma ≥10 mm
Number of subjects: 3121

Group type: EXPERIMENTAL
Intervention: Patients with villous adenoma
Number of subjects: 3121

Group type: EXPERIMENTAL
Intervention: Patients with adenoma with high-grade dysplasia
Number of subjects: 3121
Study: 16137274

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 584
Study: 11893345

Group type: EXPERIMENTAL
Intervention: Fluoxetine (10-80 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10459082

Group type: EXPERIMENTAL
Intervention: Long‐chain Triglycerides (LCTs)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Medium‐chain Triglycerides (MCTs)
Number of subjects: 76
Study: 7842196

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 10 ppm
Number of subjects: 35

Group type: COMPARATOR
Intervention: Prostacyclin (PGI2)
Number of subjects: 35
Study: 2104988

Group type: EXPERIMENTAL
Intervention: High-dose TRH (0.5 mg/kg) administered intravenously (IV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered intravenously (IV)
Number of subjects: 0
Study: 335498

Group type: EXPERIMENTAL
Intervention: 100-400 mg spironolactone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100-200 mg spironolactone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: spironolactone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: spironolactone with other antihypertensive regimens
Number of subjects: 40
Study: 29427176

Group type: EXPERIMENTAL
Intervention: Open-label subcutaneous golimumab 50 mg every 4 weeks (q4w) through week 12, continued for responders through week 52.
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Open-label subcutaneous golimumab 50 mg q4w through week 44 (N = 75).
Number of subjects: 433

Group type: COMPARATOR
Intervention: Double-blind subcutaneous golimumab 50 mg q4w or intravenous golimumab 2 mg/kg (weeks 16, 20, every 8 weeks [q8w]) for nonresponders.
Number of subjects: 433

Group type: COMPARATOR
Intervention: Previous adalimumab/etanercept treatment.
Number of subjects: 433
Study: 26712088

Group type: EXPERIMENTAL
Intervention: Epi-Fix
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: LockIt Plus
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Tegaderm
Number of subjects: 165
Study: 25180016

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Best conventional medical practice with SCS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Best conventional medical practice without SCS (control group)
Number of subjects: 60
Study: 22721736

Group type: EXPERIMENTAL
Intervention: Mismatching redundant amodal information (viewed cylinders while holding a rectangular cube)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching redundant amodal information (not explicitly mentioned but implied)
Number of subjects: 0
Study: 21072973

Group type: EXPERIMENTAL
Intervention: Treatment FP (fentanyl 0.02 mg kg(‐1) and propofol 12.0 mg kg(‐1) hour(‐1))
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Treatment MP (midazolam 0.3 mg kg(‐1) and propofol 12.0 mg kg(‐1) hour(‐1))
Number of subjects: 6
Study: 18682011

Group type: EXPERIMENTAL
Intervention: Individual behavioural counselling using motivational interviewing techniques
Number of subjects: 141

Group type: COMPARATOR
Intervention: Information leaflets
Number of subjects: 141
Study: 16191135

Group type: EXPERIMENTAL
Intervention: Educational intervention for physicians
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 30
Study: 12712062

Group type: EXPERIMENTAL
Intervention: Midazolam syrup
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10972633

Group type: EXPERIMENTAL
Intervention: Naratriptan 1 mg
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Naratriptan 2.5 mg
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Naratriptan 5 mg
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Naratriptan 7.5 mg
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Naratriptan 10 mg
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 643

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Naratriptan (any dose)
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Sumatriptan (any dose)
Number of subjects: 643
Study: 8761583

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (S-P) given as a single dose of 0.8-1.4 mg pyrimethamine/kg body weight
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Older children
Number of subjects: 38

Group type: COMPARATOR
Intervention: Weekly dapsone-pyrimethamine prophylactic intervention
Number of subjects: 38
Study: 1423200

Group type: EXPERIMENTAL
Intervention: Concurrent 5‐fluorouracil, cisplatin, and radiation therapy
Number of subjects: 42
Study: 2862111

Group type: EXPERIMENTAL
Intervention: Pirenzepine + Cimetidine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pirenzepine + Ranitidine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pirenzepine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 8
Study: 31679951

Group type: EXPERIMENTAL
Intervention: Moving Through Dance intervention using Google Glass for three weeks
Number of subjects: 7
Study: 29442143

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fixation strips
Number of subjects: 32
Study: 28476710

Group type: EXPERIMENTAL
Intervention: Minimally invasive interventional therapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Drug conservative therapy
Number of subjects: 128
Study: 24920862

Group type: EXPERIMENTAL
Intervention: Presence of interictal epileptiform discharges (IEDs)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No IEDs
Number of subjects: 23
Study: 22480442

Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone microspheres
Number of subjects: 62

Group type: COMPARATOR
Intervention: Long-acting injectable haloperidol or fluphenazine (stayers)
Number of subjects: 62
Study: 20417052

Group type: COMPARATOR
Intervention: SES (Sirolimus-Eluting Stent)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Dual-DES (Dual Drug-Eluting Stent)
Number of subjects: 1007

Group type: COMPARATOR
Intervention: ZES (Zotarolimus-Eluting Stent)
Number of subjects: 1007
Study: 17907073

Group type: EXPERIMENTAL
Intervention: Morphine analgesia
Number of subjects: 898

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Additional analgesia (AA)
Number of subjects: 898
Study: 15633203

Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg/day) for 8 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo once daily for 8 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg/day) for 8 weeks (crossover group)
Number of subjects: 64
Study: 11890432

Group type: EXPERIMENTAL
Intervention: HT only (standard HT care)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HT+ (Standard HT care plus music plus guided imagery)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 22
Study: 10480511

Group type: COMPARATOR
Intervention: Middle-aged women
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Both young and middle-aged women
Number of subjects: 174
Study: 9089530

Group type: EXPERIMENTAL
Intervention: Fee-for-Service (FFS) option
Number of subjects: 3655

Group type: EXPERIMENTAL
Intervention: Hospital-based Fee-for-Service (FFS) dental patients
Number of subjects: 3655

Group type: COMPARATOR
Intervention: Hospital HMO
Number of subjects: 3655
Study: 1993791

Group type: EXPERIMENTAL
Intervention: Inferior left ventricular patch as an anode
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Inferior left ventricular patch as a cathode
Number of subjects: 40
Study: 6389814

Group type: EXPERIMENTAL
Intervention: Written instructions for mixing the solution along with a pre‐marked container (group I)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Written instructions only (group II)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Premarked container only (group III)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Neither written instructions nor premarked container (group IV)
Number of subjects: 86
Study: 29779435

Group type: EXPERIMENTAL
Intervention: Content acquisition and reading comprehension intervention (comprehension canopy, essential words, knowledge acquisition, team-based learning)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Comparison condition (standard instructional practices)
Number of subjects: 690
Study: 30308388

Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/d; 3/1 schedule) plus fulvestrant (500 mg)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (500 mg)
Number of subjects: 521
Study: 26853648

Group type: EXPERIMENTAL
Intervention: CMVPepVax vaccine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 36
Study: 24072758

Group type: EXPERIMENTAL
Intervention: Alcohol assessment and feedback (group 1)
Number of subjects: 7809

Group type: EXPERIMENTAL
Intervention: Alcohol assessment only without feedback (group 2)
Number of subjects: 7809

Group type: COMPARATOR
Intervention: No contact, neither assessment nor feedback (group 3)
Number of subjects: 7809
Study: 21640257

Group type: EXPERIMENTAL
Intervention: VEGF Trap‐Eye 0.5 mg every 4 weeks
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: VEGF Trap‐Eye 2 mg every 4 weeks
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: VEGF Trap‐Eye 0.5 mg every 12 weeks
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: VEGF Trap‐Eye 2 mg every 12 weeks
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: VEGF Trap‐Eye 4 mg every 12 weeks
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: VEGF Trap‐Eye (all groups combined)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: VEGF Trap‐Eye (2 mg q4wk and 2 mg q12wk)
Number of subjects: 159
Study: 19459420

Group type: EXPERIMENTAL
Intervention: One combined inhaled drug containing glucocorticosteroids (GCS) and long‐acting beta2‐agonists (LABA)
Number of subjects: 47
Study: 16850291

Group type: EXPERIMENTAL
Intervention: Autologous disc chondrocyte transplantation (ADCT) plus discectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discectomy alone (Control)
Number of subjects: 0
Study: 15296796

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (700 IU/day for 1 month)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study: 11782045

Group type: EXPERIMENTAL
Intervention: Experimental therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 0
Study: 9028818

Group type: EXPERIMENTAL
Intervention: QSC + SBF
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: QSC + EBF
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: QSC
Number of subjects: 427
Study: 8101126

Group type: EXPERIMENTAL
Intervention: Alprazolam and exposure (combined treatment)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Alprazolam and relaxation (psychological placebo)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo and exposure
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo and relaxation (double placebo)
Number of subjects: 154